Shanghai Rightongene Biotechnology Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 208.96 million compared to CNY 205.31 million a year ago. Revenue was CNY 208.96 million compared to CNY 205.31 million a year ago.

Net income was CNY 42.74 million compared to CNY 28.36 million a year ago. Basic earnings per share from continuing operations was CNY 0.89 compared to CNY 0.68 a year ago. Diluted earnings per share from continuing operations was CNY 0.89 compared to CNY 0.68 a year ago.